Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence

Ivan D. Montoya, Kenzie L. Preston, Richard Rothman, David A. Gorelick

Research output: Contribution to journalArticlepeer-review

Abstract

Combinations of medications are often used in neuropsychiatry to enhance treatment efficacy. This 8-week, open-label study tested the combination of bupropion (≤300mg) and bromocriptine (≤7.5 mg) daily in 34 cocaine-dependent (DSM-IIIR) outpatients also receiving weekly individual counseling. The first 18 subjects spent one week at maximum dose; the next 16 spent three weeks. Both groups showed significant reductions in self-reported cocaine use, with no significant change in proportion of urine toxicology tests positive for cocaine. There were no significant differences in outcome between groups. These results suggest that the combination of bupropion and bromocriptine is safe in cocaine addicts, but provide ambiguous evidence of its efficacy.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalAmerican Journal of Drug and Alcohol Abuse
Volume28
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Bromocriptine
  • Bupropion
  • Cocaine
  • Dependence
  • Treatment

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence'. Together they form a unique fingerprint.

Cite this